644.61
Idexx Laboratories Inc stock is traded at $644.61, with a volume of 562.43K.
It is up +0.16% in the last 24 hours and down -8.80% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$643.59
Open:
$642.39
24h Volume:
562.43K
Relative Volume:
1.00
Market Cap:
$51.47B
Revenue:
$4.30B
Net Income/Loss:
$1.06B
P/E Ratio:
49.30
EPS:
13.076
Net Cash Flow:
$1.04B
1W Performance:
-3.86%
1M Performance:
-8.80%
6M Performance:
+3.27%
1Y Performance:
+39.96%
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
IDEXX Laboratories, Inc. (IDXX): A Bull Case Theory - Finviz
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Qiagen (QGEN) and InnovAge Holding (INNV) - The Globe and Mail
Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating - marketscreener.com
4 Analysts Have This To Say About IDEXX Laboratories - Benzinga
IDEXX Laboratories (IDXX) Positioned to Benefit from Growing Aging Pet Market - Finviz
Fidelity Growth Strategies Fund Avoids IDEXX Laboratories (IDXX) Due to Questionable Growth Durability - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Idexx Laboratories (IDXX) and West Pharmaceutical Services (WST) - The Globe and Mail
Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 - marketscreener.com
Idexx Laboratories executive vice president sells $4.6 million in stock - MSN
IDEXX: A Great Business Trapped By A Demanding Valuation (NASDAQ:IDXX) - Seeking Alpha
Hantz Financial Services Inc. Decreases Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Alta Capital Management LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Rep. April McClain Delaney Sells Off Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
A Quick Look at Today's Ratings for IDEXX Laboratories Inc(IDXX.US), With a Forecast Between $730 to $805 - 富途牛牛
IDEXX Laboratories Analysts Cut Their Forecasts Following Q4 Results - Benzinga
Roku To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 - marketscreener.com
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $730 - 富途牛牛
UBS Adjusts IDEXX Laboratories PT to $730 From $750 - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 earnings call transcript - MSN
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 Earnings Call Transcript - Insider Monkey
BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 - marketscreener.com
IDEXX Laboratories, Inc. $IDXX Shares Sold by Villere ST Denis J & Co. LLC - MarketBeat
Thrivent Financial for Lutherans Has $38.68 Million Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories: Can This Quiet Diagnostics Powerhouse Still Surprise Wall Street? - AD HOC NEWS
BTIG Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $800 - 富途牛牛
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 14.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Idexx Laboratories (IDXX) Margin Strength Reinforces Bullish Narrative Despite Premium P/E - Sahm
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips - Investing.com Canada
IDEXX Laboratories (NASDAQ:IDXX) Trading Down 6.9%Should You Sell? - MarketBeat
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories Inc (IDXX) Q4 2025 Earnings Call Highlights: - GuruFocus
IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - The Globe and Mail
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
Why Is IDEXX Labs Stock Falling Today? - Benzinga
IDEXX Laboratories Q4 Earnings Call Highlights - MarketBeat
IDEXX Laboratories (IDXX) Reports Strong Q4 2025 Performance - GuruFocus
RSI Alert: Idexx Laboratories (IDXX) Now Oversold - Nasdaq
IDEXX Laboratories Reports 14% Q4 Revenue Growth Driven by Premium Instrument Placements - Market Business Insights
IDEXX falls 4% following in-line 2026 guidance - Seeking Alpha
IDEXX beats the Street on Q4 results, issues initial 2026 guidance - Mainebiz
AI for investors - MLQ.ai
IDEXX Laboratories (NASDAQ:IDXX) Updates FY 2026 Earnings Guidance - MarketBeat
Earnings Summary: IDEXX Laboratories Q4 - Benzinga
IDEXX forecasts 2026 above estimates, but cautious clinic visit outlook weighs on shares - Reuters
IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics - marketscreener.com
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
IDEXX Laboratories (IDXX) Q4 FY25 sales rise in double digits - AlphaStreet
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):